• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Biologics, Immunotherapies, and Cytotoxic Chemotherapy for Hepatocellular Carcinoma following Current Recommendations by the BCLC: A Review of Agents.根据巴塞罗那临床肝癌（BCLC）当前推荐意见，用于肝细胞癌的生物制剂、免疫疗法和细胞毒性化疗：药物综述
Semin Intervent Radiol. 2024 Mar 14;41(1):84-91. doi: 10.1055/s-0043-1778660. eCollection 2024 Feb.
2
Treatment allocation in hepatocellular carcinoma: Assessment of the BCLC algorithm.肝细胞癌的治疗分配：BCLC算法评估
Ann Hepatol. 2016 Jan-Feb;15(1):82-90. doi: 10.5604/16652681.1184233.
3
Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations.多模态治疗肝细胞癌：临床实践如何符合国际建议。
Liver Int. 2018 Sep;38(9):1624-1634. doi: 10.1111/liv.13888. Epub 2018 Jul 15.
4
Treatment patterns and outcomes in hepatocellular carcinoma: Real-world experience in Greece from the retrospective OPAL study.肝细胞癌的治疗模式与结局：来自希腊回顾性OPAL研究的真实世界经验。
Ann Gastroenterol. 2025 Mar-Apr;38(2):195-207. doi: 10.20524/aog.2025.0950. Epub 2025 Feb 28.
5
Surgical resection for large hepatocellular carcinoma and those beyond BCLC: systematic review with proposed management algorithm.手术切除治疗大肝癌和巴塞罗那分期 C 期肝癌以外的肝癌：系统综述与提出的治疗方案算法。
Langenbecks Arch Surg. 2023 Apr 12;408(1):144. doi: 10.1007/s00423-023-02881-w.
6
Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma.巴塞罗那临床肝癌C期肝细胞癌的多模式管理
Liver Cancer. 2014 Oct;3(3-4):405-16. doi: 10.1159/000343861.
7
Treatment and prognosis study of spontaneous rupture hemorrhage in hepatocellular carcinoma: Recommendations for adding the A1 stage to the BCLC staging system.肝细胞癌自发破裂出血的治疗和预后研究：建议在 BCLC 分期系统中增加 A1 期。
Cancer Med. 2024 May;13(10):e6952. doi: 10.1002/cam4.6952.
8
A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group.在三级转诊中心，手术治疗肝细胞癌的有效适应证和结果概览：是否符合 EASL/AASLD 建议？：HCC 东西研究组的一项观察性研究。
Ann Surg. 2013 May;257(5):929-37. doi: 10.1097/SLA.0b013e31828329b8.
9
Applicability of the BCLC staging system to patients with hepatocellular carcinoma in Korea: analysis at a single center with a liver transplant center.BCLC分期系统在韩国肝细胞癌患者中的适用性：在设有肝移植中心的单一中心进行的分析
Korean J Hepatol. 2011 Jun;17(2):113-9. doi: 10.3350/kjhep.2011.17.2.113.
10
Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study.巴塞罗那临床肝癌分期和肝移植对肝细胞癌患者的生存获益：一项多中心队列研究。
Lancet Oncol. 2011 Jul;12(7):654-62. doi: 10.1016/S1470-2045(11)70144-9. Epub 2011 Jun 16.

引用本文的文献

1
SIRT1 Modulates the Photodynamic Anticancer Activity of 5,10,15-Triethoxycarbonyl P(V) Corrole in Hepatocellular Carcinoma.SIRT1调节5,10,15-三乙氧羰基磷（V）卟啉在肝癌中的光动力抗癌活性。
Pharmaceuticals (Basel). 2025 Aug 20;18(8):1226. doi: 10.3390/ph18081226.

本文引用的文献

1
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.特瑞利木单抗联合度伐利尤单抗治疗不可切除肝细胞癌。
NEJM Evid. 2022 Aug;1(8):EVIDoa2100070. doi: 10.1056/EVIDoa2100070. Epub 2022 Jun 6.
2
Concurrent transarterial radioembolization and combination atezolizumab/bevacizumab treatment of infiltrative hepatocellular carcinoma with portal vein tumor thrombosis: a case report.经动脉放射性栓塞与阿替利珠单抗/贝伐单抗联合治疗伴门静脉肿瘤血栓形成的浸润性肝细胞癌：病例报告
J Liver Cancer. 2022 Mar;22(1):69-74. doi: 10.17998/jlc.2022.03.09. Epub 2022 Mar 21.
3
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗序贯根治性转化（ABC转化）用于不可切除、不适合经动脉化疗栓塞术的中期肝细胞癌患者
Liver Cancer. 2022 Jul 27;11(5):399-406. doi: 10.1159/000526163. eCollection 2022 Sep.
4
The Evolution of the MELD Score and Its Implications in Liver Transplant Allocation: A Beginner's Guide for Trainees.终末期肝病模型（MELD）评分的演变及其在肝移植分配中的意义：实习生入门指南
ACG Case Rep J. 2022 May 4;9(5):e00763. doi: 10.14309/crj.0000000000000763. eCollection 2022 May.
5
Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma.肝移植和降期治疗肝细胞癌的十年结果。
JAMA Surg. 2022 Sep 1;157(9):779-788. doi: 10.1001/jamasurg.2022.2800.
6
Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study.雷莫西尤单抗治疗的真实世界数据，包括接受过两种或更多种全身治疗的患者：一项多中心研究。
Cancers (Basel). 2022 Jun 16;14(12):2975. doi: 10.3390/cancers14122975.
7
Combination Therapy With Lenvatinib and Radiofrequency Ablation for Patients With Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh Class A Liver function: A Pilot Study.乐伐替尼与射频消融联合治疗超出米兰标准且肝功能为Child-Pugh A级的中期肝细胞癌患者：一项前瞻性研究。
Front Oncol. 2022 May 4;12:843680. doi: 10.3389/fonc.2022.843680. eCollection 2022.
8
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.BCLC 策略用于预后预测和治疗推荐：2022 年更新版。
J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018. Epub 2021 Nov 19.
9
Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice.阿替利珠单抗和贝伐单抗作为晚期肝细胞癌的一线治疗：常规临床实践中的实际考量
World J Hepatol. 2021 Sep 27;13(9):1132-1142. doi: 10.4254/wjh.v13.i9.1132.
10
Immune Checkpoints in Cancers: From Signaling to the Clinic.癌症中的免疫检查点：从信号传导到临床应用
Cancers (Basel). 2021 Sep 12;13(18):4573. doi: 10.3390/cancers13184573.

Biologics, Immunotherapies, and Cytotoxic Chemotherapy for Hepatocellular Carcinoma following Current Recommendations by the BCLC: A Review of Agents.

作者信息

Gurtatta Rajangad S, Whalen Sydney E, Ray Charles E

机构信息

University of Illinois College of Medicine, Chicago, Illinois.

Department of Radiology, University of Illinois College of Medicine, Chicago, Illinois.

出版信息

Semin Intervent Radiol. 2024 Mar 14;41(1):84-91. doi: 10.1055/s-0043-1778660. eCollection 2024 Feb.

DOI:10.1055/s-0043-1778660
PMID:38495256
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10940041/
Abstract
摘要